<ul data-eligibleForWebStory="false"><li>Jefferies has raised its target price on Mankind Pharma Ltd. to Rs 3,000 from Rs 2,870, maintaining a 'buy' rating due to expected recovery and significant improvements in the coming quarters.</li><li>The first and second quarters are anticipated to be pivotal for Mankind Pharma, with India Rx growth expected to normalize later in the fiscal year. The synergies from the BSV acquisition are projected to reflect in the 26% Ebitda margin guidance for FY26.</li><li>Jefferies highlighted the favorable risk-reward profile of Mankind Pharma, making it their top pick. The company is likely to deliver 19% returns in the base case and over 30% in the bull case, with a downside estimated at less than 10% in case of delays in recovery.</li><li>Mankind Pharma, established in 1995, is a leading pharmaceutical company in India with a strong presence in various therapeutic areas. The company operates in both domestic and international markets.</li></ul>

Mankind Pharma Gets Target Price Hike — Why Jefferies Calls It Top Pick

Discover more